Difference between revisions of "Ipilimumab (Yervoy)"

Revision as of 15:42, 14 September 2019

General information

Class/mechanism: Anti-CTLA-4 antibody. CTLA-4 is a negative regulator of T-cell activation and ipilimumab interferes with the ability of CTLA-4 to interact with its ligands CD80/CD86. CTLA-4 blockade results in T-cell activation and proliferation, and it is suspected that its anti-neoplastic activity may be due to T-cell mediated anti-tumor immune responses.^[1]^[2]^[3]
Route: IV
Extravasation: no information

YERVOY Risk Evaluation and Mitigation Strategy (REMS) Site^[4]

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

3/25/2011: FDA approved "for the treatment of unresectable or metastatic melanoma."
10/28/2015: FDA approved for "adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy."
4/16/2018: FDA approved to be used in combination with Nivolumab (Opdivo) "for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma.
Indicated for treatment of adult and pediatric patients 12 years of age and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, in combination with nivolumab.

Also known as

Code names: BMS-734016, MDX-010
Brand name: Yervoy

References

[insert-1] 1.0 ^1.1 ^1.2 Ipilimumab (Yervoy) package insert

[2] Ipilimumab (Yervoy) package insert (locally hosted backup)

[3] Yervoy manufacturer's website

[4] YERVOY Risk Evaluation and Mitigation Strategy (REMS) Site

[5] Ipilimumab (Yervoy) patient drug information (Chemocare)

[6] Ipilimumab (Yervoy) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

[5]

[6]

@@ Line 25: / Line 25: @@
 *10/28/2015: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm469944.htm FDA approved] for "adjuvant treatment of patients with cutaneous [[Melanoma | melanoma]] with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy."
 *4/16/2018: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604685.htm FDA approved] to be used in combination with [[Nivolumab (Opdivo)]] "for the treatment of intermediate or poor risk, previously untreated [[Renal cell carcinoma|advanced renal cell carcinoma]].
+* Indicated for treatment of adult and pediatric patients 12 years of age and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic [[Colon_cancer|colorectal cancer]] that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, in combination with nivolumab.
 ==Also known as==